Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2013


SMi - Diabetes: Secondary Complications, Regulation and Innovation

01 Oct 2013 - 02 Oct 2013 - London, UK



Bookmark and Share


Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. 

SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.  

“This conference is an excellent one stop shop to up-skill on current issues in diabetes therapy. I’m happy to chair what will no doubt be a very stimulating session.” – Phil Ambery, Medical Director, GlaxoSmithKline

Key Reasons to Attend:

Receive clinical updates on novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors

Utilise biomarkers and imaging for the development of novel therapies for diabetes

Discuss new therapeutic targets to reduce hypertension, hyperkalaemia and endothelial inflammation in diabetes

Remain abreast of new EU and FDA guidelines on clinical trials on risk-benefit assessment

Capitalise on the effects of targeting RAAS, CCN2 and CCN3 inhibitors

Review clinical results from the DEMAND study

Key Speakers Include: 

James F. List, Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb

John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital

Martin Siman, Director, Design and Interpretation Centre of Excellence, AstraZeneca

Philip Ambery, Director, Clinical Development, GlaxoSmithKline

Sandra Souza, Team Lead, Molecular Biomarkers, PPDM , Merck Sharp & Dohme 

Diabetes: Secondary Complications, Regulation and Innovation, promises to be a unique platform for networking, problem solving and learning from timely case studies. This really is a unique event not to be missed.

Book online at www.smi-online.co.uk/goto/2013diabetes-conference28.asp

Contact John Collins: Email: jcollins@smi-online.co.uk Tel: +44 (0)207 827 6734




Further information
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!